Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ:AMGN)

277.29 -5.35 (-1.89%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
52 53 Next >
Amgen Layoffs 2023: What to Know About the Latest AMGN Job Cuts
Wall street is buzzing over Amgen layoffs today. The biotech company announced it laid off 300 of its U.S. employees. 
Via InvestorPlace
Here's How Much You Would Have Made Owning Amgen Stock In The Last 15 Years
Via Benzinga
Earnings Preview: Amgen
Via Benzinga
Can Market Sustain Upward Momentum In Tech-Heavy Earnings Week? Apple, Amazon, AMD, Alphabet, Ford Among Key Quarterly Reports To Watch
With a full week of earnings behind us, it’s time to take stock of the fourth-quarter reporting season so far. Overall, the news flow has been mixed, although tech earnings have grossly disappointed. 
Via Benzinga
2 Top Passive-Income Stocks to Own in 2023
These dividend stocks can deliver both downside protection and capital appreciation. 
Via The Motley Fool
Analyst Expectations for Amgen's Future
Via Benzinga
2 Top Biotech Stocks to Buy for the Long Haul
Developing new products will be key to the success of both of these biotech leaders. 
Via The Motley Fool
Dogs of the Dow 2023: 5 Dividend Stocks for Income Investors
The 2023 Dogs of the Dow feature several stocks investors should consider for their income portfolios. Here are the top five picks. 
Via InvestorPlace
6 Dividend Growth Stocks
Interested in knowing about companies that are paying their shareholders even bigger dividends than before? Today I want to tell you about six dividend growth stocks that just increased their... 
Via Talk Markets
3 Dividend Stocks You Can Safely Hold for Years
Look for the top companies in businesses the world perpetually needs. 
Via The Motley Fool
Analyst Views Novo Nordisk's Upcoming Obesity Drug Data To Lay Grounds For Eli Lilly's Tirzepatide
Cantor Fitzgerald published around 40-page deep dive ahead of Novo Nordisk A/S's (NYSE: NVO) SELECT CV outcomes study, which is guided to complete in ~mid-2023.  
Via Benzinga
$100 Invested In Amgen 15 Years Ago Would Be Worth This Much Today
Via Benzinga
If You Invested $100 In This Stock 20 Years Ago, You Would Have $500 Today
Via Benzinga
Building A Dividend Growth Portfolio To Meet Your Unique Needs
A look at how investors can utilize creative strategies that apply to their own financial situation to build portfolios that work for them. 
Via Talk Markets
Illumina Shares Tank After Annual Guidance Fall Short Of Expectations
Via Benzinga
The Dogs of the Dow Worked Last Year, But This Strategy Could Make You More Money in 2023
Meet the Dogs of the S&P. 
Via The Motley Fool
5 Top Pharma Stocks of 2022 to Buy for the Long Haul
The biggest drug company blockbusters bring in billions of dollars, which is one of the reasons to consider these top Pharma stocks. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
3 Top U.S. Stocks to Watch in January
Considering their potential, all three stocks look like good opportunities today. 
Via The Motley Fool
CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks
Genetic medicine is a top theme now for biotech stocks. Other trends are heating up too. 
Via Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Could the Dow Jones Keep Outperforming the Nasdaq Composite in 2023?
The Dow crushed the Nasdaq in 2022, but that's no guarantee of a lasting trend. 
Via The Motley Fool
10 Best Stock Traders In Congress In 2022 (Spoiler: Nancy Pelosi Isn't No. 1)
A new report was out about the performance of members of the U.S. Congress who bought and sold stocks and options in 2022. The report broke down unusual trading activity from members of Congress and... 
Via Benzinga
Meet the 2023 Dogs of the Dow
After a tumultuous year, this simple strategy that outperformed sagging markets might be just what you're looking for. 
Via The Motley Fool
10 Highest-Yielding Dow Jones Stocks Heading Into 2023
The stock market had a rough 2022 with many of the top indexes down double digits. Among the stock indexes that were down was the Dow Jones Industrial Average. With declining prices, dividend yields on... 
Via Benzinga
2 Unstoppable Dividend Growth Stocks to Buy in 2023 and Beyond
Nothing is more reassuring to an income investor than a boost to the dividend. 
Via The Motley Fool
The Battles Brewing That Could Stoke Already Red-Hot Eli Lilly Stock
Investors are closely watching two key spaces that could spark Lilly stock. 
Via Investor's Business Daily
2 Market-Beating Stocks to Buy in 2023 and Hold Forever
For these companies' shareholders, it may be tempting to take profits right now. But both stocks can keep growing for a while. 
Via The Motley Fool
2 No-Brainer Biotech Stocks to Buy Right Now
Vertex Therapeutics and Amgen have the building blocks for long-term success. 
Via The Motley Fool
Alphabet To $115? Here Are 10 Other Price Target Changes For Thursday
Stifel raised argenx SE (NASDAQ: ARGX) price target from $471 to $478. Stifel analyst Alex Thompson maintained a Buy rating on the stock. argenx shares rose 1.1% to $387.07 in pre-market trading. 
Via Benzinga
< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
52 53 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.